Recombinant epidermal growth factor (Center for Genetic Engineering and Biotechnology/Praxis Pharmaceuticals)

N/A

Report date: 2022/02/21 14:31:57

Base Information

Drug NameRecombinant epidermal growth factor (Center for Genetic Engineering and Biotechnology/Praxis Pharmaceuticals)
Drug Alias NameHeberprot-P 75rhEGF (CIGB/Praxis Pharmaceuticals)rhuEGF (CIGB/Praxis Pharmaceuticals)hrecEGF (CIGB/Praxis Pharmaceuticals)rhEGF(Center for Genetic Engineering and Biotechnology/Praxis Pharmaceuticals) +[7] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionEpidermal growth factor receptor erbB1 agonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsDiabetic Foot
Global Approved IndicationsDiabetic Foot
Approved Indications in ChinaN/A
Original Approved Country/TerritoryCuba
Original Approved Date2007/09/01
Country/TerritoryCubaMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesCenter For Genetic Engineering And BiotechnologyPraxis Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesCenter For Genetic Engineering And BiotechnologyHuake Pharmaceutical Intellectual Property Consulting Center
Inactive CompaniesN/A
Active IndicationsDiabetic Foot
Inactive IndicationsN/A

Other Information

ATC CodeD03
Related LinksWikipediaKEGG